Oncology biotech IN8bio (INAB) plans to raise $75 million at a $325 million market cap. IN8bio is focused on developing cancer therapies by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company’s lead candidates, INB-200 and INB-100, are targeting glioblastoma and a subset of patients with leukemia. Both are in Phase 1 trials, with topline data expected in 2021 and 2022, respectively.
Clinical stage biotech Inhibikase Therapeutics (IKT), which is developing kinase inhibitors for Parkinson's (PD) and related disorders, plans to raise $15 million at a $142 million market cap. Its lead candidate, IkT-148009, is being developed for PD and related disorders that arise inside and outside the brain. Inhibikase has filed two INDs for IkT-148009 and expects to begin the first dosing of patients shortly after the IPO.
Sustainable food-focused SPAC Natural Order Acquisition (NOACU) plans to raise $200 million. The company is led by Chairman Sebastiano Castiglioni, who is a Partner at Blue Horizon Group, and CEO Paresh Patel, who manages his private investment office Sandstone Investments.
| U.S. IPO Calendar | |||
|---|---|---|---|
| Issuer Business |
Deal Size Market Cap |
Price Range Shares Filed |
Top Bookrunners |
| Inhibikase Therapeutics (IKT) Atlanta, GA |
$15M $142M |
$10 - $12 1,363,636 |
ThinkEquity |
| Clinical stage biotech developing kinase inhibitors for Parkinson's and related disorders. | |||
| Natural Order Acquisition (NOACU) Weston, MA |
$200M $250M |
$10 20,000,000 |
Chardan Barclays |
| Blank check company focusing on technologies and products related to sustainable plant-based food and beverages. | |||
| IN8bio (INAB) New York, NY |
$75M $325M |
$15 - $17 4,687,500 |
Barclays Cantor Fitz. |
Phase 1 oncology biotech developing allogeneic gamma-delta T cell therapies. |
|||
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.